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Abstract
Photodynamic therapy (PDT) is an oxygen-dependent, light-activated, and locally destructive drug treatment of cancer. 
Protoporphyrin IX (PpIX)-induced PDT exploits cancer cells’ own innate heme biosynthesis to hyper-accumulate the natu-
rally fluorescent and photoactive precursor to heme, PpIX. This occurs as a result of administering heme precursors (e.g., 
aminolevulinic acid; ALA) because the final step of the pathway (the insertion of ferrous iron into PpIX by ferrochelatase to 
form heme) is relatively slow. Separate administration of an iron chelating agent has previously been demonstrated to sig-
nificantly improve dermatological PpIX-PDT by further limiting heme production. A newly synthesized combinational iron 
chelating PpIX prodrug (AP2-18) has been assessed experimentally in cultured primary human cells of bladder and derma-
tological origin, as an alternative photosensitizing agent to ALA or its methyl or hexyl esters (MAL and HAL respectively) 
for photodetection/PDT. Findings indicated that the technique of iron chelation (either through the separate administration 
of the established hydroxypyridinone iron chelator CP94 or the just as effective combined AP2-18) did not enhance either 
PpIX fluorescence or PDT-induced (neutral red assessed) cell death in human primary normal and malignant bladder cells. 
However, 500 µM AP2-18 significantly increased PpIX accumulation and produced a trend of increased cell death within 
epithelial squamous carcinoma cells. PpIX accumulation destabilized the actin cytoskeleton in bladder cancer cells prior to 
PDT and resulted in caspase-3 cleavage/early apoptosis afterwards. AP2-18 iron chelation should continue to be investigated 
for the enhancement of dermatological PpIX-PDT applications but not bladder photodetection/PDT.
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Introduction
Photodynamic therapy (PDT) is based on the activation of 
a photosensitizer by visible light and the transfer of energy 
to molecular oxygen, creating reactive oxygen species 
(ROS) that induce oxidative stress and thus cell death [1]. 
5-Aminolevulinic acid (ALA)-induced-PDT exploits the 
cell’s own innate heme biosynthesis pathway to generate 
the natural endogenous photosensitizer protoporphyrin IX 
(PpIX; the precursor to heme). Free heme inhibits further 
ALA synthesis, and this natural regulation step can be 
bypassed by purposefully adding exogenous ALA, which 
then drives the pathway to operate at maximal capacity. 
Cellular accumulation of PpIX occurs as the final step (the 
insertion of ferrous iron  (Fe2+) into PpIX by ferrocheletase 
to form heme) is relatively slow [1]. This process occurs 
at a faster rate in malignant cells (which generally have 
upregulated and less well controlled heme biosynthesis) 
than in normal cells and so a temporally selective window 
occurs when red light (635 nm) can be applied to activate 
PpIX within the tumor, while sparing surrounding normal 
cells [1].
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Within dermatology, a topical cream containing the 
small, soluble precursor to PpIX (ALA or its methyl ester, 
methyl-aminolevulinate (MAL; Metvix, Galderma, UK)) is 
applied to the area of skin to be treated [2]. Although effec-
tive treatment outcomes associated with excellent cosmesis 
have been demonstrated in licensed lesions (actinic kerato-
sis, Bowen’s disease and superficial basal cell carcinoma 
(BCC)) when the disease remains superficial [3–5] or alter-
natively in mild to moderate inflammatory acne [6], efforts 
continue to increase the efficacy and extend the applications 
of topical PpIX-PDT particularly to treat thicker nodular 
BCC or acrally located conditions [7]. Poor penetration 
into deeper layers can be improved clinically by employ-
ing more lipophilic ALA derivatives (e.g., MAL) [8–10] 
or nano-emulsion formulations (e.g., ALA; Ameluz, Spirit 
Healthcare, UK) [5] and by performing skin pre-treatments 
[11–13]. There is also interest in applying PDT beyond der-
matology, in a wide range of oncological/non-oncological 
applications [14].
PpIX’s natural fluorescence can also be employed for 
photodetection of bladder cancer [15–17] or fluorescence-
guided surgical resection of high-grade glioma of the brain 
using orally administered ALA [18], as PpIX exhibits char-
acteristic red fluorescence (at 635 nm and 700 nm) when 
excited by blue light (410 nm). Cells that have accumulated 
PpIX can therefore be identified through non-invasive fluo-
rescence monitoring [19]. The more lipophilic hexyl ester 
derivative, HAL (Hexvix, Photocure, Norway) [20] doubled 
PpIX accumulation in a human bladder cancer photodetec-
tion pilot study, with PpIX being evenly distributed through-
out the urothelial layers [15, 21]. A subsequent clinical study 
of HAL for urothelial cell carcinoma also demonstrated 
promising results [22], and photodetection of bladder can-
cer with HAL now has FDA and European approval [23]. 
Although this technique has increased tumor detection, the 
long-term impact on recurrence rates still remains unclear 
[24].
Using an iron chelating agent to reduce intracellular iron 
can inhibit the conversion of PpIX to heme, resulting in 
greater PpIX accumulation. ALA and hydroxypyridinone 
iron chelating agent co-administration has been previously 
demonstrated to successfully increase PpIX-PDT efficacy 
in vitro, in vivo, and during clinical application [25–28]. 
1,2-diethyl-3-hydroxypyridine-4-one (CP94) has been dem-
onstrated to be the best iron chelator for this application as it 
diffuses through the cell membrane better than other clini-
cally available iron chelators and has a greater selectively for 
iron than other transition metals [29, 30]. A novel-combined 
conjugate, AP2-18, which links ALA to CP94 via a cleav-
able ester (Scheme 1) has been derived [31] to overcome 
co-administration issues by releasing the two agents simul-
taneously following cellular uptake and ubiquitous cytosolic 
esterase release [32, 33]. Promising initial experimental 
findings of AP2-18 activity within human normal skin fibro-
blasts and skin cancer cells [34, 35] have been extended 
here as well as investigated within human cells of bladder 
origin for the first time to assess the feasibility of AP2-18 as 
an alternative to ALA/MAL administration in skin or HAL 
application in bladder for fluorescence photodetection and/
or PDT treatment.
Materials and methods
Normal human primary bladder epithelial cells and two 
types of human urinary bladder transitional cell carcinoma 
(RT-4, from a well differentiated tumor stage T2/grade 
G1 and aggressive RT-112, from a tumor grade G2) were 
cultured aseptically in 96-well plates for experimentation 
(primary bladder cells and RT-4, ATTC, Germany; RT-112, 
ECACC, UK). Additional experimentation was conducted 
with human primary epithelial squamous carcinoma cells 
(A431, ECACC, UK).
Initial investigations tested AP2-18 against the clini-
cally approved prodrugs ALA and HAL (250, 500 or 
1000 µM) ± the hydroxypyridinone iron-chelator, CP94. 
Fluorescence intensity (excitation λ = 405 ± 12 nm; detection 
λ = 635 ± 12 nm) was measured hourly (in arbitrary units) 
with a Bio-tek Synergy HT plate reader (Swindon, UK) as 
an indication of PpIX in RT-112 cells (n = 5) over 10 h at 
37˚C following the generation of standard curves (Fig. 1a–c) 
to demonstrate that fluorescence was linearly aligned to syn-
thetic PpIX (Sigma, UK) concentration. Further PpIX fluo-
rescence experimentation utilized up to 1500 µM AP2-18 
and monitored all three bladder cell types (n = 5) as well as 
skin cancer cells up to 6 h (a minimum of in triplicate on 
three separate occasions) with MAL replacing HAL in this 
cell type as MAL is utilized clinically within dermatology 
(unlike HAL). Background low light intensity conditions 
Scheme  1  The molecular structure of the hydroxypyridinone iron 
chelating PpIX prodrug, AP2-18
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were employed in the laboratory as a precaution through-







































































Fig. 1  Panels a–c demonstrate the linear relationship between varying 
amounts of synthetic PpIX (up to 0.1, 1.0, and 10.0  µM PpIX respec-
tively) and fluorescence intensity (in arbitrary units) observed during 
preliminary experimentation. Panels d–f record PpIX fluorescence accu-
mulation measured in hourly intervals over 10 h in RT-112 bladder can-
cer cells (n = 5). RT-112 cells were treated with increasing concentrations 
of d ALA + CP94; e HAL + CP94 and f the composite prodrug AP2-18. 
CP94 was added in equimolar concentrations. Statistical comparison 
(Welch two sample t-test) of fluorescence intensities between each indi-
vidual treatment group at 6  h and 10  h produced p-values > 0.05. Bars 
indicate the standard error of the mean. Panel g illustrates mean PpIX 
fluorescence measured following 6-h incubation in normal primary blad-
der cells and RT-4 & RT-112 bladder cancer cells (n = 5). The cells were 
treated with ALA alone (5-Ala), ALA + CP94 (5-Ala +), HAL alone 
(Hal), HAL + CP94 (Hal +), or the composite drug AP2-18 in increasing 
concentrations (250–1500  µM). CP94 was added in equimolar concen-
trations. Statistical comparison between individual experiments (Welch 
two-sample t-test) confirmed that PpIX accumulation in RT-4 cells was 
significantly higher than in RT-112 and primary bladder cells in all 
experiments with p-values ≤ 0.001. The statistical significances within the 
experimental groups are otherwise indicated as *p ≤ 0.05, **p ≤ 0.005 and 
***p ≤ 0.001 respectively. Bars indicate the standard error of the mean
Fig. 1  (continued)
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Photodynamic effects were investigated within all cell 
types after 6-h incubation with the respective prodrugs, to 
match earlier investigations and because PpIX accumula-
tion observed appeared consistent up to this time point. Pre-
liminary experimentation established that 500 µM ALA and 
250 µM HAL were most effective in the bladder cell types. 
These concentrations were therefore adopted for continu-
ity and because higher concentrations did not significantly 
increase RT-112 PpIX accumulation. For the evaluation 
of the new composite drug AP2-18, 250–1500 µM was 
employed in the three bladder cell types and ≤ 1500 µM 
in the skin cancer cells using a clinical Aktilite LED array 
(Galderma, UK) as the PDT light source. Bladder cells 
(n = 5) were irradiated 6 h after treatment (λ = 635 nm; 
dose =  30Jcm−2) and cell viability/death assessed 16 h later. 
The skin cancer cells were treated similarly except the clini-
cal dermatology light dose of  37Jcm−2 was employed with 
500 µM MAL and 250 µM ALA (because these concentra-
tions previously produced effective results in this cell type). 
Appropriate dark (drug only), blank (no drug), and positive 
(lysed) control groups were also conducted in parallel to the 
test groups.
Sixteen hours after PDT, the 96-well plates were 
centrifuged (900 rpm; 3 min), and the adherent cells 
utilized for the neutral red assay. As viable cells take 
up neutral red, the dye can be extracted, and its color 
intensity utilized to indicate how many survived [36]. 
A 7.5-µl neutral red solution was added to each well 
for 2 h. The supernatant was removed; the cells washed 
twice with phosphate buffered saline (PBS), and the 
neutral red dissolved with 200 µl solubility buffer (49 
parts  H2O, 50 parts 99.9% ethanol and one part glacial 
acid). Absorbance as a measurement of cell viability 
was recorded at 540 nm. The number of surviving cells 
was presented in reference to the untreated positive 
control, which was set to 100%. The increase in cell 
death after PDT in comparison to the control cells was 
in all cases significantly higher, which confirmed the 
cytotoxic effect of PDT. Statistical analysis was con-
ducted utilizing the Welch two sample t-test (within 
Microsoft Excel), with p-values < 0.05 being considered 
significant.
Confocal laser scanning microscopy (Leica TCS SP8 
with HyD; Milton Keynes, UK) was undertaken on all 
three bladder cell types in a separate but complimentary 
series of experiments. Sterile coverslips were placed in a 
6-well plate and coated with attachment factor (Sigma, 
UK). Fifty thousand cells in 2 ml media were seeded onto 
the coverslips and incubated (37 °C/5%  CO2) overnight. 
Treatment was conducted as above before the cells were 
fixed. Growth media was removed, and 4% para-formal-
dehyde in PBS pH7 (PFA) added to just cover the cells for 
10 min at room temperature. This was removed, and the 
coverslips washed twice for 5 min with PBS/0.2% triton to 
permeabilize the cells, followed by a further three washes 
with PBS to remove any traces of detergent/PFA. Antibody 
and subsequent incubation steps took place in a humidified 
chamber. Phalloidin 488 (Abcam, Cambridge, UK; diluted 
1:1000 in PBS/0.2% triton for 1 h at room temperature and 
under light protection) and Hoechst 33,342 (Sigma, UK; 
final concentration of 1:10,000 for the last 15 min) stains 
were utilized to highlight f-actin and DNA respectively. 
Caspase-3 was also qualitatively visualized via immunohis-
tochemistry conducted with anti-human cleaved caspase-3 
and Alexa 546. Cells were blocked with 5% goat serum 
in PBS/0.2% triton for 1 h at room temperature. This was 
removed before incubation with rabbit anti-human cleaved 
caspase-3 (Cell Signaling Technology, London, UK; 1:400 
in 5% goat serum in PBS/0.2% triton) overnight at 4˚C. The 
next day, the primary antibody was washed off thoroughly 
with PBS/0.2% triton and PBS before adding the secondary 
antibody (antibody goat anti rabbit Alexa546 (Invitrogen, 
ThermoFisher, Paisley, UK; 1:400 in PBS) and incubat-
ing for 4–6 h at room temperature. For counterstaining, 
phalloidin 488 and Hoechst 33,324 were added for the last 
1 h and 15 min respectively, as described above. After the 
incubation steps, the coverslips were washed three times 
with PBS/0.2% triton and another three times with PBS 
before being mounted on microscope slides with ProLong 
Diamond Antifade (Invitrogen, ThermoFisher, Paisley, 
UK). For live cell images, 30,000 RT4 cells were seeded 
into a 35-mm diameter imaging µ-dish with a glass bot-
tom (Ibidi, Graefelfing, Germany) and treated with 500 µM 
AP2-18 for 6 h (this concentration of AP2-18 was selected 
after considering the findings presented in Figs.1d–g and 
2 in detail and concluding that the higher doses investi-
gated did not convey additional benefit at this time point). 
Treatment media were replaced with RPMI/5% FBS/10% 
HEPES without phenol red. For single scan live cell imag-
ing, the incubation box that houses the stage and micro-













Fig. 1  (continued)
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Results
Human bladder cell findings
Generation of standard curves demonstrated that PpIX fluo-
rescence was linearly aligned to concentration (Fig. 1a–c). 
Near linear PpIX fluorescence was produced up to 6 h in all 
cases by AP2-18 in the RT-112 bladder cancer cells evalu-
ated with ALA or HAL incubated with an equimolar amount 
of the iron chelator CP94 (Fig. 1d–f). The progression fol-
lowed a similar gradient within each experimental group, 
and the fluctuation (indicated by the error bars) was rela-
tively small. After 6 h, the fluorescence emissions diverged 
a little, as reflected in the higher standard errors presented. 
There were also indications with 1000 µM HAL + CP94 in 
particular that the accumulation of PpIX fluorescence was 
slightly slower after this time point. Statistical analysis indi-
cated that fluorescence levels at 6 and 10 h were not signifi-
cantly different from one another. Although the fluorescence 
intensities generally increased over time, they did not neces-
sarily increase with increasing concentrations of the prod-
rug. RT-112 cells treated with 500 µM ALA + CP94 gener-
ated more PpIX than when treated with 1000 µM (Fig. 1d). 
The same observation was made when RT-112 cells were 
treated with HAL + CP94, where the highest fluorescence 
levels were reached with 250 µM (Fig. 1e). AP2-18 appeared 
more dose dependent in this cell type, although the high-
est individual measurement of PpIX fluorescence recorded 
was also with 500 µM (Fig. 1f). The differences in fluores-
cence emissions from 250 to 1000 µM were not statistically 
significant. PpIX fluorescence accumulated by the combina-
tional prodrug AP2-18 was not dissimilar to that produced 
by ALA + CP94 or HAL + CP94 administered separately.
PpIX accumulated by all three bladder cell types with all 
eight treatment variations is presented (Fig. 1g). RT-4 cells’ 
fluorescence exceeded primary bladder and RT-112 cells 
with all the variations considered, up to four times in inten-
sity and reaching 15-17A.U. (two sample Welch t-test, p-val-
ues 0.0050–0.0001). For RT-112 and primary bladder cells, 
fluorescence levels hardly reached 10A.U. Although CP94 
addition to ALA or HAL did produce slightly elevated PpIX 
accumulation in all cell types, this was not statistically sig-
nificant. PpIX accumulation was lowest in primary bladder 
cells treated with 250 or 500 µM AP2-18 (1.6 and 3.3A.U. 
respectively), which were both significantly lower than the 
higher concentrations of AP2-18 or ALA/HAL ± CP94. 
Once the AP2-18 concentration reached 1000 µM, the com-
binational drug was just as effective at accumulating PpIX 
in this cell type as all the other prodrug combinations tested 
and increasing to 1500 µM AP2-18 did not deliver further 
improvement. Although the arbitrary PpIX levels observed 
were much higher, the same basic trend was observed in 
the RT-4 cells, i.e., significantly lower PpIX accumulating 
with 250 or 500 µM AP2-18 than all the other experimental 
variations (with PpIX fluorescence doubling between these 
two concentrations) and all other groups only being margin-
ally different and hence insignificant on statistical analysis 
(p > 0.05). The PpIX levels produced within the RT-112 
cells were all reasonably similar to one another with no clear 
trends being identified.
Fig. 2  Mean percentage cell death recorded in normal bladder cells 
and RT-4 & RT-112 bladder cancer cells following PDT conducted at 
6 h (λ = 635 nm; light dose =  30Jcm−2) as assessed by the neutral red 
assay normalized to a reference of untreated control cells. The cells 
were treated with ALA alone (5-Ala), ALA + CP94 (5-Ala +), HAL 
alone (Hal), HAL + CP94 (Hal +), or the composite drug AP2-18 in 
increasing concentrations (from 250 to 1500  µM). CP94 was added 
in equimolar concentrations. Any statistical significance (Welch two-
sample t-test) detected was indicated as *p ≤ 0.05. Bars indicate the 
standard error of the mean
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The neutral red values of the cells that survived PDT 
(drug light interval = 6 h) were subtracted from the val-
ues of the treatment control cells (Fig. 2). The results 
therefore represent the level of cell death presented as a 
percentage. The variation observed between groups was 
less marked than when measuring PpIX fluorescence. 
Generally, RT-4 cells seemed to be more sensitive to 
PDT than RT-112 cells, which was in keeping with the 
fluorescence findings (Fig. 1g), although the differences 
in cytotoxicity were not found to be statistically differ-
ent in all but one case (PDT cytotoxicity was signifi-
cantly greater with 500 µM AP2-18 in RT-4 rather versus 
RT-112 cells (p < 0.05)). Cell death in primary bladder 
cells was on par with the rates of cell death observed 
in RT-112 cells, which was again in keeping with the 
previous PpIX measurements (Fig. 1g). The addition of 
CP94 to the individual prodrug incubations did not con-
vey increased PDT cytotoxicity in these cells of bladder 
origin and with HAL appeared to reduce it in two of the 
three instances investigated albeit in a non-significant 
manner (Fig. 2).
Human epithelial squamous carcinoma cell findings
As the findings in the cells of bladder origin were unlike 
our previous observations of iron chelation, where we 
had always observed significant enhancement of PpIX 
accumulation within cells of dermatological origin even 
if this had not always been translated into increased cell 
death on irradiation [34, 35], further experimentation 
within human epithelial squamous carcinoma cells was 
undertaken. Initial PpIX monitoring experimentation 
(Fig. 3) clearly demonstrated that iron chelation signifi-
cantly enhanced PpIX fluorescence accumulation in this 
cell type, with the highest dose of AP2-18 investigated 
(500 µM) significantly (p < 0.001) outperforming separate 
administration of CP94 with either ALA or MAL, even 
though the addition of separate CP94 had already signifi-
cantly improved (p < 0.001) both ALA and MAL PpIX 
accumulation. The effectiveness of these PDT regimes in 
this cell type was also clearly demonstrated when com-
pared with the corresponding non-irradiated dark control 
groups (Fig. 4a). Generally, the addition of an iron chela-
tor either as separate CP94 or the combinational prod-
rug AP2-18 at the doses investigated did not convey any 
substantial additional cytotoxic effect over the already 
highly effective ALA alone or MAL alone PDT protocols 
(Fig. 4b). However, a visual trend towards greater cell 
kill (that reached statistical significance (p < 0.01) with 
MAL + CP94) was nonetheless evident with the higher 
dose of 500 µM AP2-18 employed with this 6-h drug light 
interval (Fig. 4b).
Confocal microscopy findings
Confocal microscopy of the cytoskeleton revealed a thick 
layer of f-actin enveloped the well attached untreated 
RT-112 control cells with delicate lamellipodia and filo-
podia protrusions (lower arrow Fig. 5a). Cell–cell contacts 
were intact and F-actin accumulated in the cytosol as rather 
short filaments (upper arrows Fig. 5a). Nuclei were evenly 
sized with a smooth surface. Despite being viable, RT-112 
PDT HAL only control cells detached in large rafts from 
the bottom of the culture dishes, and confocal microscopy 
indicated a distinct lack of f-actin through reduced phal-
loidin 488 green fluorescence and emerging gaps in the 
cell–cell junctions (white arrow Fig. 5b). F-actin started to 
depolymerize, and structural elements associated with cell 
attachment disappeared. The nuclei were smaller and denser 
(yellow arrow Fig. 5b). PDT with ALA and AP2-18 (Fig. 5c, 
d respectively) further reduced phalloidin 488 fluorescence; 
f-actin was fragmented/degraded, and the cytoskeleton struc-
tural elements were missing with large gaps between cells 
(white arrows Fig. 5c, d). Blue spots of condensed depos-
its of nuclear DNA and a fine blue nuclear rim were also 
observed (yellow arrows Fig. 5d).
RT-4 cells and primary bladder cells stayed adherent in 
prodrug control groups (Fig. 5e, g, h respectively). Cell–cell 
junctions were mostly intact and the nuclei also appeared 
normal. Stabilizing actin stress fibers were present. Closer 
inspection revealed that the lamellipodia lacked filopodia 
(arrows Fig. 5e) and that the outer membrane had started 























































Fig. 3  Mean PpIX fluorescence measured after 6-h incubation in pri-
mary epithelial squamous carcinoma cells (A431; n = 3). The cells 
were treated with ALA ± CP94, MAL ± CP94 or the composite drug 
AP2-18 in increasing concentrations (250 and 500  µM). CP94 was 
added in equimolar concentrations. Statistical significance (Welch 
two-sample t-test) between 500 µM AP2-18 and the other experimen-
tal groups and also between paired treatment conditions is indicated 
as ***p ≤ 0.001. Bars indicate the standard error of the mean
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cytoskeleton of RT-4 cells was completely disintegrated 
(Fig. 5f). In a number of cells, small but dense spots of 
f-actin were observed orbiting the nucleus. Normal primary 
bladder cells had a large cell body with filopodia extending 
from beyond the lamellipodia on the leading edge (white 
arrow Fig. 5g) but also large bundles of filopodia on the rear 
end of the cell (red arrow Fig. 5g). After exposure to AP2-18 
(Fig. 5h), the cell structure seemed unchanged with neither 
f-actin degradation nor signs of blebbing. Following PDT 
however, the leading edge lamellipodia gave way to tufts 
of filamentous f-actin protein winding through the cytosol 
(white arrow Fig. 5i); the rear filopodia bundles retracted 
(red arrow Fig. 5i) and the nucleus appeared fragmented 
(yellow arrow Fig. 5i).
Caspase-3 release (red) was also visualized before and 
after PDT (representative images Fig. 5j–m). The insert in 
Fig. 5j shows a classic apoptotic cell in the non-treated RT-4 
control group. The shrunken cell body is full of cleaved cas-
pase-3 and condensed chromatin. Primary bladder cells after 
250 µM AP2-18 PDT showed no signs of caspase-3 release, 
but the nuclei were deformed/partially fragmented, and the 
f-actin lamellipodia interrupted (yellow and white arrows 
respectively Fig. 5k). The absence of caspase-3 and cytotox-
icity findings suggest that PDT-induced cell death with these 
parameters resulted from primary necrosis in this normal 
cell type. F-actin was reduced to a thin layer that engulfed 
the RT-4 cells after 500 µM AP2-18 PDT, and lumps of 
DNA in the nuclei were visible (yellow arrows Fig. 5l). Tiny 
dots of red caspase-3 fluorescence scattered throughout the 
cytosol were also detected (white arrow Fig. 5l), which were 
not present in the control experiments. RT-112 cells after 
500 µM ALA PDT looked similar to RT-4 cells with con-
densed nuclei and aggregated nuclear DNA being observed 
(yellow arrow Fig. 5m). Tiny dots of cytosolic caspase-3 
were also present with increased intensity. RT-4 and RT-112 
cells post-PDT therefore appeared in to be in the early stages 
of apoptosis.
Discussion
Previously intercepting heme synthesis through iron che-
lator addition significantly enhanced PpIX accumulation/
PDT cytotoxicity in human skin cancer and normal fibro-
blasts [26, 28, 29]. This was not replicated in the normal 
and malignant bladder cells investigated here (Figs. 1g and 
2), although it was demonstrated once again within human 
skin cancer cells (Figs. 3 and 4). The levels of fluores-
cence recorded were more dependent on the bladder cell 
type than on the treatment variations (Fig. 1g). Doubling 
prodrug concentrations in RT-112 cells did not double PpIX 
accumulation (Fig. 1d–f). RT-4 cells produced significantly 
higher levels of PpIX than other cell types (Fig. 1g), possibly 
because of their metabolic rate. These higher levels did not 
necessarily translate into significantly higher PDT cytotoxic-
ity (Fig. 2). Instead, even the modest level of RT-112 PpIX 
accumulation already reduced the cell viability produced on 
irradiation by ~ 66%. Average RT-4 cell death was 85%. So, 
although PpIX accumulation was increased by nearly 200%, 
RT-4 cell death was only increased by 20%, indicating that 
in different cell types, different levels of cell damage may be 
required to induce cell death.
Iron chelator addition, either as separate CP94 or prod-
rug linked as AP2-18, did not seem to have any conse-
quential influence, either on PpIX fluorescence (Fig. 1g) 
or bladder cancer cell death following PDT (Fig.  2). 
This general lack of iron chelator enhancement prob-
ably resulted in the new combinational prodrug AP2-18 



































































































Fig. 4  Mean percentage cell survival of primary epithelial squa-
mous carcinoma cells (A431; n = 3) following PDT conducted at 6 h 
(λ = 635  nm; light dose =  37Jcm−2) as assessed by the neutral red 
assay. The cells were treated with ALA ± CP94, MAL ± CP94, or 
the composite drug AP2-18 in increasing concentrations. CP94 was 
added in equimolar concentrations. Panel a Non-irradiated dark con-
trol groups and irradiated PDT groups. Panel b Irradiated PDT data 
alone. Statistical significance (Welch two-sample t-test) between 
500 µM AP2-18 and the other experimental groups on panel b is indi-
cated as **p ≤ 0.01. Bars indicate the standard error of the mean
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above the existing prodrugs in these bladder cells (unlike 
observed in dermatological cells [34, 35]), although it was 
equally as effective as separate co-administration.
The normal bladder cells were also as suscepti-
ble to PDT-induced cytotoxicity as the cancer cells 
(Fig. 2; ~ 71%) which would not be desirable for clini-
cal photodetection/PDT application. To our knowledge, 
there is no record of investigating normal primary bladder 
cells for PDT, with little PDT effect on immortal UROtsa 
cells and N1 fibroblasts PDT-resistance being reported 
instead [37–39]. Here, ≤ 500 µM AP2-18 produced the 
least amount of PpIX in normal bladder cells (Fig. 1g) 
and correspondingly had the highest survival rate post-
PDT (Fig. 2). As the same treatment parameters produced 
satisfactory RT-4 cancer cell cytotoxicity (Fig. 2), this may 
indicate that it is possible to improve the normal versus 
malignant contrast at this concentration.
In skin cancer cells, iron chelation consistently, signifi-
cantly (p < 0.001) improved PpIX accumulation (Fig. 3) when 
separate CP94 was co-administered with ALA/MAL but was 
most pronounced when the combinational iron chelating PpIX 
prodrug AP2-18 was employed. 500 µM AP2-18 significantly 
increased (p < 0.001) PpIX accumulation above that produced 
by all other treatment regimens, corresponding with previ-
ous findings [34, 35]. Following PDT (Fig. 4), although the 
highest AP2-18 concentration produced a visual trend towards 
greater cytotoxicity, this only reached statistical significance 
(p < 0.01) when considered against MAL + CP94. Increasing 
the AP2-18 dose further may have resolved this but gener-
ally iron chelation works best when the treatment parameters 
Fig. 5  Confocal microscope 
images documenting f-actin 
depolymerization and cleaved 
caspase-3 in bladder cells after 
PDT. RT112, RT-4, and normal 
bladder cells seeded on cover 
slips were treated as detailed. 
The fixed cells were stained for 
nuclear DNA (Hoechst, blue) 
and f-actin (phalloidin 488, 
green) and underwent immuno-
histochemistry with anti-human 
cleaved caspase 3 and Alexa 
546 (red). The confocal micro-
scope images are representative 
for the controls, treatment with 
prodrug alone, or prodrug-PDT. 
Panels a–i show the dramatic 
decrease in f-actin and the 
loss of cytoskeletal structure 
elements. A detail of image e 
shows a row of characteristic 
f-actin blebbing on the cell 
membrane. Panels j–m docu-
ment caspase-3 release. Panel 
j represents the untreated RT-4 
control cells and the detail of 
a classic apoptotic cell, which 
were very low in numbers; k 
normal primary bladder cells 
after AP2-18-PDT; l RT-4 can-
cer cells after AP2-18-PDT and 
m RT-112 cells after ALA-PDT. 
All images were taken with the 
same settings [Leica SP8 with 
HyD]. The scale bars in panels 
a, m apply to all images, except 








b: Hal – control
c: 5-Ala – PDT
d: AP2-18 – PDT
RT-112 e: Hal – control
f: AP2-18 – PDT RT-4
g: control
h: AP2-18 – control
i: AP2-18 – PDT
prim bladder
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are limited and thus sub-optimal [35]. The standard prodrug 
regimens utilized were already highly effective (Fig. 4) kill-
ing ≥ 75% of skin cancer cells without any augmentation 
being necessary. Future work should therefore continue to test 
AP2-18 within dermatological cells and explore more limited/
sub-optimal standard prodrug treatment regimens with shorter 
drug-light intervals to try to replicate the clinical scenario at 
the base of thicker nodular BCC tumors where the current 
licensed protocol is currently producing inadequate results 
(without repeat treatments).
Battah et al. [32] found that ALA and CP94 directly 
linked via an ester function (like AP2-18) was the least 
efficient in a series of conjugates that they synthesized but 
was slightly less hydrophilic than ALA and so should be 
slightly better at entering cells [32]. Hydrophilicity could 
be decreased further by extending the ester bridge between 
ALA and CP94 but this would also increase molecular 
size. Many experimental factors differed (cell type; culture 
conditions; light source), making direct comparison diffi-
cult. No additional iron was employed here for instance as 
this is not required for effective tissue culture, and it is also 
hard to anticipate the optimal cytosolic iron levels required 
[40, 41]. Adding excess  Fe2+ would selectively favor the 
chelating compound, while quenching PpIX accumulation 





f-acn nucleus cleaved caspase-3
j
Fig. 5  (continued)
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It is also important to consider the potential deleterious 
effect that adding ever increasing amounts of iron chelating 
compounds could have on this complex series of biochemi-
cal events. Once the heme biosynthesis pathway is operating 
in an optimal manner for the maximal PDT effect possible, 
with very limited ferrocheletase activity left remaining to 
inhibit through additional iron chelation, further sequester-
ing of cellular free iron could result in reduced ROS pro-
duction and thus less cell death on irradiation, as iron can 
catalyze ROS generation following PpIX-induced PDT [41].
Palasuberniam et al. [42] have determined that ferroche-
latase activity is an important determinant of tumor response 
to iron chelation with deferoxamine (DFO). Knock down cell 
types without ferrochelatase activity were more sensitive 
to ALA-PDT, but this alteration completely abolished the 
enhancement effect of DFO iron chelation. Although the 
ferrochelatase activity of the specific cell types employed 
here has not been established, it is postulated that this factor 
may at least in part explain the differing findings observed 
between the human cells of bladder and skin origin. A431 
epithelial squamous carcinoma cells are known to express 
high levels of epidermal growth factor receptor (EGFR) 
[43] and lactase dehydrogenase (indicating elevated glycolic 
metabolism) [44] and strong expression of the PPARGC1A 
gene (suggesting mitochondrial biogenesis and oxidative 
phosphorylation) [44]. Although ALA-PDT has been inves-
tigated in RT-112 bladder cancer cells previously [45], we 
are not currently aware of their ferrochelatase activity, and 
so this would be an interesting avenue of future research.
Confocal microscopy imaging also revealed that prod-
rug-induced PpIX accumulation alone already destabilized 
the actin cytoskeleton in bladder cancer cells (particularly 
RT-112) prior to PDT (Fig. 5). Iron depletion (which could 
result from more PpIX being available than normal to bind 
 Fe2+) can indirectly lead to f-actin depolymerization [46] 
and again would reduce the potential potentiating effects of 
iron chelation. The primary bladder cells, however, managed 
to maintain their cytoskeletal integrity under prodrug treat-
ment. PDT further damaged the cytoskeleton in bladder can-
cer cells. Visualization of caspase-3 release post-PDT indi-
cated that both bladder cancer cell types were in the early 
stages of apoptosis, whereas absence of caspase-3 in normal 
bladder cells suggested cell death from primary necrosis.
Conclusion
Although all tested prodrugs raised PpIX levels significantly 
in treated cells and caused considerable cell death after PDT, 
none of the prodrugs ± CP94 iron chelation or the combined 
conjugate AP2-18 stood out as an optimal treatment regime 
in the bladder cells investigated. This is in direct contrast 
to the findings with human skin cancer cells, where both 
separate CP94 iron chelating supplementation to standard 
prodrug administration as well as the novel combinational 
iron chelating PpIX-prodrug AP2-18, conveyed significant 
advantage particularly in respect to PpIX accumulation. 
It is therefore concluded that the mechanism of action of 
PpIX-induced PDT is both complex and highly cell type 
dependent, and so potential enhancement techniques such 
as iron chelation cannot be universally applied without 
thorough prior investigation. These findings support further 
investigation of iron chelator enhancement of PpIX-induced 
PDT for dermatological applications, however, not bladder 
photodetection/PDT.
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